Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 70 years old.
- People who have been newly diagnosed with multiple myeloma, confirmed using standard international diagnostic guidelines.
- People whose disease is measurable through blood or urine tests showing certain protein levels, or through a specific blood test measuring free light chains (confirm with trial site).
- People whose doctors have determined them suitable to receive high-dose chemotherapy followed by a stem cell transplant using their own cells.
- People whose myeloma has at least one very high-risk feature, such as two or more specific high-risk genetic changes in the cancer cells, myeloma that has spread to soft tissues outside the bone marrow, or a higher-than-normal number of cancer cells circulating in the blood.
- People whose tumour cells test positive for two specific proteins called BCMA and GPRC5D.
- People whose liver and kidney function results fall within acceptable ranges as defined by the trial (confirm with trial site).
- People who are able to understand the trial and are willing to sign a written consent form.
Who may not be able to join:
- People with an active condition called amyloidosis, where abnormal proteins build up in organs.
- People whose myeloma has spread to the central nervous system (the brain or spinal cord).
- People who have previously received a therapy targeting BCMA, or any CAR-T cell therapy.
- People with an active hepatitis B or hepatitis C infection.
- People with a known HIV infection.
- People whose life expectancy is estimated to be less than 6 months.
- People who are pregnant or breastfeeding.
- People with serious uncontrolled problems affecting the heart, lungs, brain, or other major organs.
- People whom the principal investigator determines to be unsuitable for the trial for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 86-022-23909171
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Sustained MRD-negative rate; MRD negativity rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.